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Purpose: To retrospectively assess clinical outcomes and toxicity profile of prostate
cancer patients treated with delayed dose-escalated image-guided salvage radiotherapy
(SRT) for macroscopic local recurrence after radical prostatectomy (RP).
Material and Methods: We report on a cohort of 69 consecutive patients with
local recurrence after RP and no evidence of regional or distant metastasis who were
referred for salvage radiotherapy between 2007 and 2016. SRT consisted of 64–66Gy
(2 Gy/fraction) to the prostatic bed followed by dose escalation to 72–74Gy (2Gy/fraction)
to the macroscopic disease. All patients received concurrent short-term androgen
deprivation therapy (ADT). Biochemical recurrence-free survival (bRFS) and clinical
progression-free-survival (cPFS) were depicted using Kaplan-Meier method. Multivariable
Cox proportional hazards regression assessed predictors of survival outcomes. Baseline,
acute, and late urinary and gastrointestinal (GI) toxicity rates were reported using
CTCAE v4.03.
Results: Median time from RP to SRT was 66 months (IQR: 32–124). Median pre-SRT
prostate-specific antigen (PSA) was 2.7 ng/ml (IQR: 0.9–6.5). Median follow-up after SRT
was 38 months (IQR: 24–66). The 3- and 5-year bRFS were 58 and 44%, respectively.
The 3- and 5-year cPFS were 91 and 76%, respectively. Median time from SRT to clinical
disease progression was 102 months (IQR 77.5–165). At baseline, 3 patients (4%) had
grade 3 urinary symptoms. Six patients (9%) developed acute and six patients (9%)
developed late grade 3 urinary toxicity. Five patients (7%) had acute grade 2 GI toxicity.
No acute grade 3 GI toxicity was reported. Late grade 3 GI toxicity was reported in one
patient (1.5%).
Conclusions: Delayed dose-escalated SRT combined with short-course ADT for
macroscopic LR after RP was associated with 44% bRFS and 76% cPFS at 5 years.
Albeit improved patient stratification is warranted, these data suggest that delayed SRT
provides inferior tumor control compared to early intervention.
Keywords: prostate cancer, salvage radiation, local recurrence, macroscopic recurrence, postoperative
radiotherapy
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INTRODUCTION
About 20–40% of all localized prostate cancer patients
undergoing radical prostatectomy (RP) develop biochemical
recurrence (1, 2). In the absence of overt distant metastasis,
salvage radiotherapy (SRT) to the prostatic bed is commonly
offered as a potential curative treatment for patients with
biochemical or manifested local recurrence (LR).
Several studies have shown that SRT efficacy is highly
dependent on the pre-salvage prostate-specific antigen (PSA)
level (3–5). However, many urologists including at our institution
are reluctant to offer early SRT in the absence of radiologically
confirmed local disease. Overall, the two main arguments
favoring this approach include lack of conclusive overall survival
benefits from prospective clinical trials and a potential increased
risk of worsened functional outcomes (6).
The purpose of the current study was to evaluate oncologic
outcomes and toxicity rates in a cohort of patients treated with
delayed dose-escalated image-guided SRT for macroscopic LR
after RP.
MATERIALS AND METHODS
Patient Population
Following approval of institutional and regional ethical review
boards, we reviewed charts of 69 consecutive patients who
received image-guided SRT after RP due to isolated LR in
the prostatic bed between 2007 and 2016 at our Department
of Radiation Oncology. Diagnostic imaging included pelvic
magnetic resonance imaging (MRI) with or without Choline
Positron Emission Tomography/Computed Tomography
(PET/CT). Most LR were biopsy proven (41/69 patients, 59%).
Baseline patient and disease characteristics as well as baseline
(pre-SRT), acute and late toxicities were prospectively collected.
SRT Protocol
Gross Target Volume (GTV) encompassed the visible
macroscopic lesion at the site of recurrence. The GTV
delineation on CT simulation was based on available imaging
modality that included pelvic MRI with or without Choline
PET/CT. The clinical target volume for the entire prostate
bed (CTV_prostate_bed) included the prostate/seminal vesicle
surgical bed at risk of harboring microscopic disease. The first
planning target volume (PTV1) included the CTV_prostate_bed
with a margin of 10mm in all directions except 8mm posteriorly.
The second planning target volume (PTV2) included the GTV
with 10 mm-margin in all directions except 8mm posteriorly.
Radiotherapy was delivered using photon-based intensity
modulated radiotherapy (IMRT) with daily cone-beam
computed tomography (CBCT) as image-guidance. A dose
of 64–66Gy (2Gy per fraction) was delivered to PTV1 followed
by a dose escalation to 72–74Gy (2Gy per fraction) to PTV2.
Normal tissue dose constraints as well as bowel and bladder
preparations consistently followed institutional guidelines. All
patients were treated with concomitant and adjuvant androgen
deprivation therapy [luteinizing hormone releasing hormone
(LHRH) agonist injections] for 6 months.
Outcome Measures
During the entire study period, follow-up after SRT was offered
at 3, 6, 12, 18, and 24 months and yearly thereafter. Follow up
consisted of office visits with review of general health, PSA testing
and physical examination including digital rectal examination
at suspicion of local progression. For patients who were unable
to attend follow up consults, information was retrieved via
electronic mail, phone correspondence, and questionnaires sent
to primary care physicians and referring urologists.
Biochemical recurrence was defined as post-SRT PSA nadir
plus 0.2 ng/ml confirmed by a second PSA rise. Clinical
progression was defined as the occurrence of a local, nodal,
and/or distant relapse. Diagnostic imaging was performed when
clinically indicated and the type of imaging was at the discretion
of the treating physician.
Baseline symptoms pre-SRT, acute and late toxicities were
tabulated and scored according to CTCAE v4.03 toxicity scale.
Late toxicity was defined as toxicity events occurring after 3
months from the end of SRT until the last follow-up date.
Statistical Analysis
The Kaplan-Meier method was used to depict the probabilities
of bRFS and cPFS after SRT. In addition, to account for
potential lead-time bias, cPFS was also calculated from the
date of RP. Multivariable Cox proportional hazards tested for
the effect of pre-SRT PSA level on bRFS and cPFS, adjusting
for pathologic stage (pT2-3a/pT3b-4), and GTV (≤ 4.25 cm3/>
4.25 cm3). Ninety-five percent confidence intervals (CI) were
calculated to assess the precision of the obtained estimates.
Statistical significance was set at a two-sided p < 0.05 (IBM SPSS
Statistics, version 21).
RESULTS
Oncologic Outcomes
Patient- and tumor-related characteristics are summarized in
Table 1. Median time from RP to biochemical recurrence was
35 months (IQR: 14–64). Median time from RP to SRT was 66
months (IQR: 32–124). Median follow-up time after SRT was 38
months (IQR: 24–66). Median pre-SRT serum PSA was 2.7 ng/ml
(IQR: 0.9–6.5).
A total of 28 patients developed biochemical recurrence
after SRT. The 3- and 5- year bRFS were 58 and 44%,
respectively (Figure 1A). Furthermore, 12 patients developed
clinical progression. The 3- and 5- year cPFS were 91 and
76%, respectively (Figure 1B). In addition, 10- and 15-year cPFS
after RP were 90 and 85%, respectively. Median time to clinical
progression after RP was 102 months (IQR: 77–156). Only 1
prostate cancer-related death was documented.
In multivariable analysis, pT3b disease and GTV > 4.25cm3
were found to be independent predictors of bRFS, but not of
cPFS (Table 2).
Toxicity
Prior to SRT, 10 patients (14%) had grade 2, and 3 patients (4%)
had grade 3 urinary symptoms, respectively, most frequently
urinary retention and incontinence. Following SRT, acute urinary
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TABLE 1 | Patient and tumor characteristics.
Variable Value
Median age at SRT (IQR in years) 71 (66–75)
Median age at RP (IQR in years) 63 (60–66)
Median time to SRT after RP (IQR in months) 66 (32–124)
Median Follow up after SRT (IQR in months) 38 (24–66)
PREOPERATIVE PSA
≤10 ng/ml 28 (40.6%)
>10 ng/ml ≤ 20 ng/ml 11 (15.9%)
>20 ng/ml 10 (14.5%)
Missing 20 (29%)
T- STAGE
pT2-3a 57(82.6%)
pT3b-4 12 (17.4%)
N-STAGE
pN0 58 (84.1%)
pN1 11 (15.9%)
GLEASON SCOREa
≤6 11 (15.9%)
7 38 (55.1%)
≥8 20 (29%)
SURGICAL MARGIN
Negative 25 (36.2%)
Positive 32 (46.4%)
Missing 12 (17.4%)
PERINEURAL INVASION
Yes 35 (50.7%)
No 16 (23.2%)
Missing 18 (26.1%)
PRE-SRT PSA
0–0.5 ng/ml 10 (14.5%)
>0.5–1 ng/ml 8 (11.6%)
>1–2 ng/ml 9 (13.1%)
>2–4 ng/ml 13 (18.8%)
>4–10 ng/ml 21 (30.4)
Above 10 ng/ml 8 (11.6%)
HISTOLOGICAL CONFIRMATION
Yes 41 (59%)
No 28 (41%)
GROSS TUMOR VOLUME
≤4.25 cm3 34 (49%)
>4.25 cm3 35 (51%)
aGleason score at prostatectomy.
toxicity grade 2 and 3 occurred in 12 (17%) and 6 patients
(9%), respectively. Twelve patients (17%) experienced grade 2,
and 6 patients (9%) grade 3 late urinary toxicity. The most
common symptoms observed after treatment were incontinence
and urinary retention. There were no GI symptoms reported
prior to SRT. Acute GI toxicity grade 2 was observed in 7 patients
(10%), while no grade 3 acute GI toxicity occurred. Late GI
toxicity grade 2 was present in 2 patients (3%) and grade 3 in one
patient (1.5%). The most frequent symptoms were diarrhea and
rectal pain. No grade 4 toxicity was reported at any time (Table 3;
Supplementary Material).
FIGURE 1 | Kaplan-Meier estimates of (A) Biochemical relapse-free survival
(bRFS) and (B) Clinical progression-free survival (cPFS).
DISCUSSION
Our work reports on a cohort of 69 patients homogeneously
treated with dose escalated image-guided SRT due to
macroscopic LR and a median pre-SRT PSA level of 2.7 ng/ml.
At a median follow-up of 38 months, the 3- and 5-year bRFS
were 58 and 44%, respectively. The 3- and 5-year cPFS were 91
and 76%, respectively. In this population, pathologic tumor stage
and tumor size (GTV) were independent predictors of bRFS, but
not of cPFS.
For high-risk prostate cancer patients, LR after RP is a
predominant pattern of treatment failure (7). For patients with
isolated LR, SRT represents a potentially curative therapeutic
option. Indeed, many clinicians favor SRT over upfront adjuvant
treatment to allow for postoperative recovery (8) and to avoid
possible over-treatment as about 40–50% of the patients can
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TABLE 2 | Univariable and multivariable logistic regression analysis of factors
associated with biochemical recurrence.
Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Factors Biochemical recurrence
T-stage 3.30 (1.35–8.05) 0.009 3.16 (1.25–8.01) 0.015
Gleason score 2.38 (0.71–7.98) 0.16 – –
Perineural invasion 2.29 (0.76–6.92) 0.14 – –
Resection margin 0.62 (0.27–1.43) 0.26 – –
Pre-RT PSA 3.70 (1.11–12.36) 0.03 2.20 (0.62–7.79) 0.2
Gross tumor volume 4.09 (1.89–8.88) <0.001 3.79 (1.69–8.47) 0.001
TABLE 3 | Gastrointestinal and urinary toxicity.
Gastrointestinal Urinary
Baseline Acute (%) Late (%) Baseline (%) Acute (%) Late (%)
Grade 2 0 7 1.5 12 13 12
Grade 3 0 0 1.5 4 7 9
achieve long-term stable disease without further treatment (9,
10). Against this rationale, the optimal timing for SRT and its
impact on oncologic outcomes and health-related quality of life
is often a matter of debate. Several large observational studies
have reported better outcomes when SRT is administrated at
a PSA ≤0.5 ng/mL (3, 11–14). Consistent with our findings, a
large systemic review including 41 retrospective studies reporting
on SRT following RP showed that pre-RT PSA is significantly
associated with bRFS rates (15). The same work shows an average
of 2.6% loss of bRFS for each incremental 0.1 ng/ml PSA increase
at the time of SRT. When assessing studies using early salvage as
defined by a pre-SRT PSA level of ≤ 0.5 ng/mL, the 5-year bRFS
probability is 71% (range: 48–81.8%), which is much higher than
the 44% probability reported in the current study (11).
Further, several large studies previously demonstrated the
impact of SRT timing on metastasis-free survival. In a
retrospective study including 1,106 patients, Stish et al. reported a
significant improvement in metastasis-free survival and prostate
cancer specific survival when post-RP patients with BCR received
SRT at PSA levels ≤0.5 ng/mL (16). These findings again argue
against prolonged monitoring of detectable post-RP PSA levels
that delay initiation of SRT. Some groups have advocated SRT
at very early stages, when pre-SRT PSA level ≤0.2 ng/mL (17).
Although controversy persists, current international guidelines
recommend the initiation of SRT at low serum PSA levels (5, 18).
A point of important debate is whether the superior outcomes
related to earlier SRT are related to lead time bias (19). Important
retrospective series cannot properly rule out this potential bias.
Thus, caution should be taken when interpreting most of the
results. Nevertheless, a recent analysis presented by Agrawal et al.
demonstrated that prostate cancer–specific mortality and all-
cause mortality calculated from the time of RP were indeed worse
for patients treated with SRT at higher PSA levels (20) These
findings corroborated those of Stish et al. (16).
The optimal SRT dose in the setting of macroscopic LR
remains unknown. In the absence of macroscopic disease, most
guidelines recommend a dose of 64–66Gy for adjuvant or SRT
(5). Retrospective data clearly support dose-escalation to the
prostate bed, however the only prospective study assessing dose
escalation in the postoperative setting (64Gy vs. 70Gy), in the
absence of detectable LR, is the SAKK 09/10 trial. This study
recently showed low rates of acute grade 2 and 3 GU and GI
toxicity with a minor impact in urinary quality of life (21).
The ongoing MAPS trial (NCT01411345) randomizes patients
with macroscopic recurrence to 68Gy in 34 fractions vs. 68Gy
in 34 fractions plus boost to MRI-guided macroscopic disease
to 76.5Gy (2.25Gy per fraction), equivalent to 80Gy in 2.0Gy
fractions. In our series, 72–74Gy was used in an unfavorable
group of patients with macroscopic LR (mostly biopsy proven)
at a median pre-SRT PSA level of 2.7 ng/ml. We found a low
toxicity profile in this series with the use of 72-74Gy; however,
longer follow-up is required. Although some experiences have
shown acceptable toxicity rates with doses up to 80Gy in the
postoperative setting (22), severe GI and GU toxicity may occur
with increased RT doses at a longer follow up (23).
Although direct comparisons between studies are challenging,
tumor control rates of the present cohort are inferior to prior
published series that used SRT at an earlier time-point (Table 4).
This is corroborated by results of the phase 3 GETUG-AFU 16
study (29), in which patients with rising post-RP PSA of 0.2–
2.0 ng/ml were randomized to SRT vs. SRT plus short term ADT.
Patients who received SRT plus short term ADT had a 5-year
bRFS of 80% (vs. 44% in our cohort).
Within limitations of retrospective series along with selection
bias, our data suggest that offering early SRT to patients with
biochemical relapse at low PSA levels, i.e., before the LR becomes
manifest, is essentially preferable. Nevertheless, at low PSA levels,
conventional imaging modalities are unable to differentiate
loco-regional vs. systemic recurrence. Therefore, prostate bed
irradiation may expose patients to unnecessary treatment. One
could argue that image-guided delayed SRT could spare many
patients from potential SRT-related side effects and quality of life
changes. Pre-SRT PSA level was not an independent predictor
of cPFS in this cohort. In addition, the vast majority of patients
who received delayed SRT survived without clinical progression;
albeit at a relatively short follow-up in a group of patients with a
long-life expectation (median age at RP was 63 years).
The use of new imaging modalities has been rapidly growing
and changing clinical management despite lack of prospective
data. Emmet et al. recently showed that PSMA PET is
independently predictive of treatment response to radiation. A
negative PSMA-PET was a strong predictor of a high response to
radiation to the prostate bed (30), also arguing against delayed
treatment. In our opinion, delayed SRT should be an option only
for unfit patients with limited life expectancy.
The present study has obvious limitations. Although this
cohort included a group of patients who were homogeneously
treated, it has a relatively small sample. Also, staging procedures
were not homogeneously performed (e.g., not all patients had
PET-CT scans); thus, some patients may have had regional or
systemic disease at the time of SRT. Lastly, 40% of the patients did
Frontiers in Oncology | www.frontiersin.org 4 February 2019 | Volume 9 | Article 12
Shelan et al. Postoperative Radiotherapy for Local Recurrence
TABLE 4 | Selected studies using early salvage radiotherapy.
References No. of patients PSA pre-RT,
ng/ml, (range)
Follow-up
(range)
bRFS
Bernard et al.
(24)
69 0.32 (0.1-0.49) 8 yr (0.6–15) 5 yr: 79.8%
Terai et al.
(25)
21 of 37 <0.15 31.9 mo
(34.3–69.8)
5 yr: 80%
Liauw et al.
(26)
34 0.27 (0.05–0.5) 72.4 mo
(5.2–136.3)
5 yr: 71%
Briganti et al.
(14)
390 <0.5
<0.3
40.6 mo 2 yr: 92.8%
5 yr: 81.8%
Stephenson
et al. (27)
181 0.4 (0.3–0.4) 33 mo
(15–132)
3 yr: 69%
5 yr: 61%
6 yr: 48%
Ost et al. (28) 48 0.3 (0.1–0.5) 53 mo
(18–132)
5 yr: 77.1%
Current series 69 2.7 ng/ml (IQR:
0.9-6.5)
38 mo
(IQR:24-66)
3 yr: 58%
5 yr: 44%
PSA, prostate-specific antigen; RT, radiotherapy; bRFS, biochemical recurrence-free
survival.
not have a confirmatory biopsy, hence we relied on the accuracy
of multiparametric MRI for the detection and treatment of the
LR. Furthermore, a longer follow up is certainly required for
more conclusive statements on the impact of delayed SRT in
cPFS, distant metastasis and prostate cancer-specific survival.
Taken together, a better stratification of patients who develop
biochemical recurrence with or without macroscopic LR after
RP is essential for more tailored approaches. Several interesting
tools have been studied including patient-specific molecular
signatures that could be used to identify the optimal radiotherapy
dose (31), radiotherapy timing (32), the efficacy of post-
operative radiotherapy (33), and also a promising combination
of quantitative multiparametric MRI data with tissue-based gene
expression (34).
CONCLUSION
Delayed image-guided SRT to macroscopic LR after RP led
to 44% bRFS and 76% cPFS at 5 years, suggesting poorer
tumor control compared to early SRT. Implementation of novel
stratification tools is of utmost importance to advance clinical
decision making in the postoperative setting.
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